Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EEC
- Development stage
- Phase 2
- Lead developer
- Chengdu Keen Biological Technology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
EEC is a recombinant Mycobacterium tuberculosis fusion protein developed by Chengdu CoenBiotech Co., Ltd. It is designed for the diagnosis of Mycobacterium tuberculosis infection in individuals aged 3 years and above. The drug functions as a diagnostic agent by eliciting a detectable immune response when administered via intradermal injection, indicating the presence of Mycobacterium tuberculosis infection.
- Other names
- modified ESAT6-CFP10 fusion proteinrecombinant Mycobacterium tuberculosis fusion protein EEC
Beyond the preview
Go deeper on EEC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EEC.